Frank Brodie is an Ophthalmology physician affiliated with San Francisco VA Medical Center. OpenAlex indexes 61 publications with 517 citations (h-index 12); ClinicalTrials.gov lists 1 registered study matched to this name.
Overview
Scholarship
indexed output and impact (OpenAlex)Distinct works indexed by OpenAlex, matched via ORCID.
Total citations across indexed works.
Hirsch index, productivity × impact (OpenAlex).
Clinical & industry
trials, payments and federal fundingContact
The practice address and phone this provider lists in the federal NPPES (CMS) registry.
Practice address
10 Koret Way
K302
San Francisco, CA 941430644
Telephone
415-476-2896Registry record last updated 24 Nov 2015.
Clinical trials
- An App-based Instructional Platform to Improve Eye Drop Recall
Sponsor: University of California, San Francisco
Registered studies on ClinicalTrials.gov where the overall official or a site investigator name-matches this physician, confirmed against known institution/geography. Latest few shown; the full list is part of the full profile.
Industry payments
18 companies reported payments to CMS in program years 2021 onward. These are public disclosures, not judgments. The latest:
- F. Hoffmann-La Roche AGProgram year20254 payments
- Genentech USA, Inc.Program year20258 payments
- Tarsus Pharmaceuticals, Inc.Program year20252 payments
Payment records matched to this physician's NPI in CMS Open Payments, program years 2021 onward.
Medicare prescribing footprint (2024)
The drugs this prescriber writes for Medicare patients, grouped by drug class and therapeutic area. Every percentage is a share of their total prescribing, so you can see what they prescribe most. These are proportions, not patient counts or dollar amounts. No condition is inferred: the claims record what was prescribed, never why.
Sensory organs
67.8%Corticosteroid21.8%Prednisolone Acetate100%Part D≥14 patientsCarbonic Anhydrase Inhibitor18.4%Dorzolamide-Timolol100%Part D<11 patients+ 2 more classes in this area
Musculoskeletal
18.4%Cyclooxygenase Inhibitor18.4%Ketorolac Tromethamine100%Part D<11 patientsMetabolism & gastrointestinal
13.8%Anticholinergic13.8%Atropine Sulfate100%Part D<11 patients
Drug classes come from the WHO ATC and U.S. National Library of Medicine (RxClass) classifications; prescribing counts come from the CMS Medicare Part D Prescribers file. Each drug is counted once, under its primary class. Medicare fee-for-service only, so no Medicare Advantage, commercial, or pediatric prescribing is included. CMS publishes this data about 17 months after the fact.
NIH funding
1 NIH research award on record, funded 2026–2026 per NIH RePORTER. The latest:
Awards in the NIH RePORTER records where a principal investigator name matches this physician at an organization in their practice state. Latest award years shown; each row links to the project record on RePORTER.
Publications
Matched to this physician's OpenAlex author record; most-cited works shown first.
- Risk of Retinal Redetachment After Cataract Surgery Following Retinal Detachment Repair in Myopic and Highly Myopic Eyes
Journal of VitreoRetinal Diseases
2026 - Subretinal Photovoltaic Implant to Restore Vision in Geographic Atrophy Due to AMD
New England Journal of Medicine
2025
Similar KOLs
Other experts from the same institution or the same specialty.
Daniel Mathalon, MD
San Francisco VA Medical Center
Daniel Bikle, MD
San Francisco VA Medical Center
Matthew Cooperberg, MD
San Francisco VA Medical Center
Raymond Swanson, MD
San Francisco VA Medical Center
A basic profile from our physician directory: identity and practice contact from the federal NPPES registry, research from OpenAlex, trials from ClinicalTrials.gov, payments from CMS Open Payments — shown itemized where we have matched records, as a count where we only have a total. This person hasn't been through our full identity-adjudication pipeline yet, so funding, congress activity and public presence aren't shown. Absence of a section means “not yet looked,” never “none found.”